adplus-dvertising
Connect with us

Health

Omicron: mRNA booster vaccine offers best protection – Medical News Today

Published

 on


Share on Pinterest
New research suggests a booster dose of an mRNA COVID-19 vaccine can protect well against the Omicron variant. Sven Hoppe/picture alliance via Getty Images
  • A recent study shows that two doses of mRNA (Pfizer-BioNTech or Moderna) and one dose of viral vector (Johnson & Johnson) COVID-19 vaccines were insufficient to produce adequate immunity to a lab-created Omicron variant or pseudovirus.
  • The Omicron pseudovirus infected cells at a higher rate than other pseudovirus variants.
  • The results demonstrated a booster dose of an mRNA COVID-19 vaccine provided the best immune protection from the Omicron pseudovirus.

Since its first detection in South Africa and Botswana in November 2021, the SARS-CoV-2 variant Omicron (B.1.1.529) has spread rapidly globally. Currently, Omicron is the leading variant of concern in the United States, accounting for about 98% of COVID-19 cases in the week ending January 8, 2022.

All viruses, including SARS-CoV-2, constantly change or mutate to form new variants. Mutations of the virus may result in the decline of the variant, while others cause the virus to thrive.

Dr. William Schaffner, professor of infectious diseases at the Vanderbilt University Medical Center in Nashville, provided some background in an MNT interview.

He explained: “When [SARS-CoV-2 viruses] mutate, they can, on occasion, […] create a variant virus that has new characteristics, you might call it a new personality, and the Omicron […] is one of those. Its surface protein compositions are similar to previous variants but a little bit different.”

Dr. Schaffner added: “So when that happens, the vaccines […] designed against the original [SARS-CoV-2] strains produce antibodies that […] [partially match] the surface structure of the Omicron variant. As a consequence, the protection is not as complete.”

There are currently three COVID-19 vaccines available in the U.S. The primary series consists of two doses of an mRNA vaccine (Pfizer-BioNTech or Moderna vaccines) or one dose of a viral vector vaccine (Johnson & Johnson).

The immune response to COVID-19 vaccines may wane over time and as new variants evolve. Boosters can help combat diminishing neutralizing antibody responses, but it is unknown how well current vaccines protect against Omicron.

This led researchers at the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard to conduct a study to investigate the effectiveness of the primary series of COVID-19 vaccines and a booster dose of an mRNA vaccine.

They study’s results appear in the journal Cell. The researchers used a laboratory test validated in previous studies called a pseudovirus neutralization assay.

The scientists created harmless versions or pseudoviruses of the original strain (wild-type), Delta, and Omicron SARS-CoV-2 viruses. The researchers then used the assay to test blood samples from 239 vaccinated participants (111 with Pfizer-BioNTech, 88 with Moderna, and 40 with Johnson & Johnson).

The study included people residing in Chelsea, MA — an area with a high rate of COVID-19 — and employees of the Massachusetts General Brigham healthcare system. Participants ranged from 18–78 years old, and 63% were female.

The study stratified participants into five groups:

  • people who received the primary vaccination series in the past 3 months and never developed COVID-19 —recently vaccinated
  • people who received the primary vaccination series in the past 6–12 months and never developed COVID-19 —distantly vaccinated
  • people who received the primary vaccination series in the past 6–12 months and developed COVID-19 — distantly vaccinated with infection
  • people who received a booster dose of the Pfizer or Moderna vaccine in the past 3 months and never developed COVID-19 — booster

The researchers measured the neutralizing antibody response of the blood samples from the four participant groups against the wild-type, Delta, and Omicron pseudoviruses. Researchers found a decreased neutralizing antibody response to the Delta and Omicron pseudovirus versus the original variant.

With the Delta pseudovirus, neutralization was slightly reduced in the recently vaccinated, distantly vaccinated with infection, and booster groups, but undetectable in the distantly vaccinated group.

However, only the participants receiving the booster vaccination demonstrated robust Omicron pseudovirus neutralization, while the other groups showed substantial decreases in neutralization capability.

When researchers compared blood samples from the group recently receiving the primary series of the COVID-19 vaccines to those receiving a booster vaccine within the last 3 months, they found that those receiving boosters had a greater scope and cross-reactivity of neutralizing antibody response to the Omicron pseudovirus.

The researchers then tested the pseudoviruses’ ability to infect cells with and without the ACE2 receptors. ACE2 receptors are necessary for cell entry of SARS-CoV-2 in the body.

As expected, none of the pseudoviruses infected cells without ACE2 receptors. In cells with ACE2 receptors, the Omicron pseudovirus infected cells at a four times higher rate than the wild-type and twice the rate of Delta.

When asked to comment on the results of the study, Dr. Schaffner expressed that the lack of assessment of the role of cell-mediated immunity was a potential limitation, “but certainly [the study offered] a […] very clear explanation on the antibody side of the immune system.”

He elaborated:

“This is an elegant study that […] [develops] some laboratory evidence that helps us explain the behavior of the virus in the real world. It reinforces the notion […] that two doses of the mRNA vaccines, although they elicit good antibody levels, are not very effective in neutralizing the Omicron virus.”

Dr. Schaffner continued: “However, if you get a booster in addition to your two doses, […] you get more antibody, and you get more diverse antibodies with that booster, [which] turned out to be really quite effective, particularly [with] Omicron. They discovered […] that Omicron pseudovirus infected cells in the laboratory much more efficiently […] than did the pseudoviruses with the other variants — [which] helps explain the increased transmissibility of Omicron.”

In a White House press briefing regarding the Omicron variant on January 5, 2022, Dr. Rochelle P. Walensky, director of the Centers for Disease Control and Prevention (CDC), outlines the organisation’s current recommendations.

She states: “Vaccines and boosters are protecting people from the severe and tragic outcomes that can occur from COVID-19 infection. We’re asking everyone to follow these four steps: Get vaccinated and get boosted, if you are eligible, wear a mask, stay home when you’re sick, and take a test if you have symptoms or looking for greater extra reassurance before you gather with others.”

Dr. Schaeffner added, “The take-home point is clear — get vaccinated [with] the booster when you become eligible immediately. That will provide the best protection.”

For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.

Adblock test (Why?)

728x90x4

Source link

Continue Reading

Health

Whooping cough is at a decade-high level in US

Published

 on

 

MILWAUKEE (AP) — Whooping cough is at its highest level in a decade for this time of year, U.S. health officials reported Thursday.

There have been 18,506 cases of whooping cough reported so far, the Centers for Disease Control and Prevention said. That’s the most at this point in the year since 2014, when cases topped 21,800.

The increase is not unexpected — whooping cough peaks every three to five years, health experts said. And the numbers indicate a return to levels before the coronavirus pandemic, when whooping cough and other contagious illnesses plummeted.

Still, the tally has some state health officials concerned, including those in Wisconsin, where there have been about 1,000 cases so far this year, compared to a total of 51 last year.

Nationwide, CDC has reported that kindergarten vaccination rates dipped last year and vaccine exemptions are at an all-time high. Thursday, it released state figures, showing that about 86% of kindergartners in Wisconsin got the whooping cough vaccine, compared to more than 92% nationally.

Whooping cough, also called pertussis, usually starts out like a cold, with a runny nose and other common symptoms, before turning into a prolonged cough. It is treated with antibiotics. Whooping cough used to be very common until a vaccine was introduced in the 1950s, which is now part of routine childhood vaccinations. It is in a shot along with tetanus and diphtheria vaccines. The combo shot is recommended for adults every 10 years.

“They used to call it the 100-day cough because it literally lasts for 100 days,” said Joyce Knestrick, a family nurse practitioner in Wheeling, West Virginia.

Whooping cough is usually seen mostly in infants and young children, who can develop serious complications. That’s why the vaccine is recommended during pregnancy, to pass along protection to the newborn, and for those who spend a lot of time with infants.

But public health workers say outbreaks this year are hitting older kids and teens. In Pennsylvania, most outbreaks have been in middle school, high school and college settings, an official said. Nearly all the cases in Douglas County, Nebraska, are schoolkids and teens, said Justin Frederick, deputy director of the health department.

That includes his own teenage daughter.

“It’s a horrible disease. She still wakes up — after being treated with her antibiotics — in a panic because she’s coughing so much she can’t breathe,” he said.

It’s important to get tested and treated with antibiotics early, said Dr. Kris Bryant, who specializes in pediatric infectious diseases at Norton Children’s in Louisville, Kentucky. People exposed to the bacteria can also take antibiotics to stop the spread.

“Pertussis is worth preventing,” Bryant said. “The good news is that we have safe and effective vaccines.”

___

AP data journalist Kasturi Pananjady contributed to this report.

___

The Associated Press Health and Science Department receives support from the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Scientists show how sperm and egg come together like a key in a lock

Published

 on

 

How a sperm and egg fuse together has long been a mystery.

New research by scientists in Austria provides tantalizing clues, showing fertilization works like a lock and key across the animal kingdom, from fish to people.

“We discovered this mechanism that’s really fundamental across all vertebrates as far as we can tell,” said co-author Andrea Pauli at the Research Institute of Molecular Pathology in Vienna.

The team found that three proteins on the sperm join to form a sort of key that unlocks the egg, allowing the sperm to attach. Their findings, drawn from studies in zebrafish, mice, and human cells, show how this process has persisted over millions of years of evolution. Results were published Thursday in the journal Cell.

Scientists had previously known about two proteins, one on the surface of the sperm and another on the egg’s membrane. Working with international collaborators, Pauli’s lab used Google DeepMind’s artificial intelligence tool AlphaFold — whose developers were awarded a Nobel Prize earlier this month — to help them identify a new protein that allows the first molecular connection between sperm and egg. They also demonstrated how it functions in living things.

It wasn’t previously known how the proteins “worked together as a team in order to allow sperm and egg to recognize each other,” Pauli said.

Scientists still don’t know how the sperm actually gets inside the egg after it attaches and hope to delve into that next.

Eventually, Pauli said, such work could help other scientists understand infertility better or develop new birth control methods.

The work provides targets for the development of male contraceptives in particular, said David Greenstein, a genetics and cell biology expert at the University of Minnesota who was not involved in the study.

The latest study “also underscores the importance of this year’s Nobel Prize in chemistry,” he said in an email.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Health

Older patients, non-English speakers more likely to be harmed in hospital: report

Published

 on

 

Patients who are older, don’t speak English, and don’t have a high school education are more likely to experience harm during a hospital stay in Canada, according to new research.

The Canadian Institute for Health Information measured preventableharmful events from 2023 to 2024, such as bed sores and medication errors,experienced by patients who received acute care in hospital.

The research published Thursday shows patients who don’t speak English or French are 30 per cent more likely to experience harm. Patients without a high school education are 20 per cent more likely to endure harm compared to those with higher education levels.

The report also found that patients 85 and older are five times more likely to experience harm during a hospital stay compared to those under 20.

“The goal of this report is to get folks thinking about equity as being a key dimension of the patient safety effort within a hospital,” says Dana Riley, an author of the report and a program lead on CIHI’s population health team.

When a health-care provider and a patient don’t speak the same language, that can result in the administration of a wrong test or procedure, research shows. Similarly, Riley says a lower level of education is associated with a lower level of health literacy, which can result in increased vulnerability to communication errors.

“It’s fairly costly to the patient and it’s costly to the system,” says Riley, noting the average hospital stay for a patient who experiences harm is four times more expensive than the cost of a hospital stay without a harmful event – $42,558 compared to $9,072.

“I think there are a variety of different reasons why we might start to think about patient safety, think about equity, as key interconnected dimensions of health-care quality,” says Riley.

The analysis doesn’t include data on racialized patients because Riley says pan-Canadian data was not available for their research. Data from Quebec and some mental health patients was also excluded due to differences in data collection.

Efforts to reduce patient injuries at one Ontario hospital network appears to have resulted in less harm. Patient falls at Mackenzie Health causing injury are down 40 per cent, pressure injuries have decreased 51 per cent, and central line-associated bloodstream infections, such as IV therapy, have been reduced 34 per cent.

The hospital created a “zero harm” plan in 2019 to reduce errors after a hospital survey revealed low safety scores. They integrated principles used in aviation and nuclear industries, which prioritize safety in complex high-risk environments.

“The premise is first driven by a cultural shift where people feel comfortable actually calling out these events,” says Mackenzie Health President and Chief Executive Officer Altaf Stationwala.

They introduced harm reduction training and daily meetings to discuss risks in the hospital. Mackenzie partnered with virtual interpreters that speak 240 languages and understand medical jargon. Geriatric care nurses serve the nearly 70 per cent of patients over the age of 75, and staff are encouraged to communicate as frequently as possible, and in plain language, says Stationwala.

“What we do in health care is we take control away from patients and families, and what we know is we need to empower patients and families and that ultimately results in better health care.”

This report by The Canadian Press was first published Oct. 17, 2024.

Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending